Urinary albumin excretion is a sensitive diagnostic and prognostic marker for renal disease. Therefore, measurement of urinary albumin must be accurate and precise. We have developed a method to quantify intact urinary albumin with a low limit of quantification (LOQ).
The accurate and precise measurement of urinary albumin excretion is important in clinical medicine because even modest increases in albuminuria predict progression of renal disease as well as cardiovascular morbidity (1) (2) (3) . Standardization of assays for this analyte will improve the management of patients with renal and cardiovascular disease. We previously reported an LC-MS assay for albumin that employed insource fragmentation and had a limit of quantification of 20 mg/L (4, 5 ) . However, because of the prognostic and diagnostic importance of even modest increases in urinary albumin excretion within the normal range, we wanted to improve the limit of quantification (LOQ) 6 of the assay in the normoalbuminuric range (Ͻ30 mg per 24 h).
Barr and coworkers were among the first to demonstrate that with a mass spectrometer as the detector peptides produced following proteolysis of a protein could be used to quantify the original intact protein (6 ) . This approach to absolute protein quantification has recently increased in popularity since protein cleavage coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) has proven viable for the quantification of several proteins (7) (8) (9) (10) (11) (12) (13) .
We report here that proteolysis of human serum albumin (HSA) followed by LC-MS/MS can be used to quantify intact urinary albumin with a low detection limit. A unique feature of our approach is the use of a full-length recombinant 15 N-labeled HSA ( 15 NrHSA) internal standard. Except for mass, this recombinant internal standard is identical to the native protein, and thus it is the ideal internal standard and can account for variations in both the digestion and LC-MS/MS processes. To the best of our knowledge, this is the first report of a full-length purified recombinant 15 Nlabeled protein being used for absolute quantification by a protein-cleavage LC-MS/MS approach.
Materials and Methods

CALIBRATOR PREPARATION
HSA was purchased from Sigma Aldrich (#A3782) and was reported by the manufacturer to have a purity of approximately 99%. An 8.20 g/L stock solution of HSA was prepared in water. The concentration was determined by ultraviolet absorption spectroscopy with a molar absorptivity of 38533 (mol/L) -1 cm -1 at 280 nm (14 ) . We prepared calibrators by adding the stock solution to a charcoal-stripped urine matrix (SeraCare Life Sciences) and performing serial dilutions to achieve concentrations of 3.13, 6.25, 12.5, 25, 50, 100, and 200 mg/L. Low, medium, and high controls were also prepared by adding the stock to the stripped urine matrix. All calibrators and controls were divided into aliquots and frozen at Ϫ80°C until used.
ANALYSIS OF URINARY ALBUMIN BY AN IMMUNOTURBIDOMETRIC ASSAY
Urinary HSA was measured in the Mayo Clinic Renal Function laboratory using an immunoturbidometric method on a Hitachi 912 chemistry analyzer with the DiaSorin SPQ™ reagent system for microalbumin. The system was calibrated using the above calibrators prepared in charcoal-stripped urine in an attempt to avoid a potential source of assay bias. Samples were centrifuged at 650g for 10 min before chemistry analysis.
PROTEOLYSIS OF CALIBRATORS AND SAMPLES
All digestions were performed using 40 L of urine, which was diluted with 135 L of 0.1 mol/L ammonium bicarbonate (Sigma-Aldrich) to normalize sample pH, followed by a 10 L addition of 161 mg/L stock 15 NrHSA internal standard. Details of the 15 NrHSA synthesis in Pichia pastoris is provided in the supplemental portion of a previous publication (15 ) . Samples were then reduced by the addition of dithiothreitol (Sigma-Aldrich) at a concentration of 10 mmol/L for 60 min at 60°C, and alkylated with iodoacetamide (Sigma-Aldrich) at 50 mmol/L for 30 min in the dark at 25°C. After reduction and alkylation, 5 L of L-(tosylamido-2-phenyl) ethyl chloromethyl ketonetreated trypsin (Sigma-Aldrich) at 1g/L in 0.1 mol/L ammonium bicarbonate was added, and the sample was digested for 1 h at 37°C. Following proteolysis, all samples were acidified with 2 L of concentrated formic acid. The final sample digest volume was 204 L.
LC-MS/MS
Independent tryptic digests of the HSA calibrators and 15 NrHSA were analyzed in the Mayo Clinic Development and Validation Center by LC-MS/MS on a Premier quadrupole time-of-flight mass spectrometer (Waters), which identified and acquired relative abundance data for the digests. A more detailed description of the LC-MS/MS conditions used can be found in a previous publication (16 ) .
The following tryptic peptides were identified by searching a human protein subset of the SwissProt protein database using MS/MS data from the quadrupole-time-offlight and the protein database search engine Mascot: QTALVELVK 534 provided the best signal responses and reproducibility; therefore only data from these peptides are reported. A BLAST search against other human proteins revealed that sequences of the LVNEVTEFAK and QTALVELVK peptides were specific to albumin (HSA Accession # P02768, gi:113576). However, it should be noted thatthesetrypticpeptidesequencesarealsoobservedinother mammalian species.
LC-MS/MS CONDITIONS
We performed quantification by LC-MS/MS using a Thermo Scientific Aria TLX2 LC system coupled to an Applied Biosystems API5000 triple-quadrupole mass spectrometer. For each run a total of 20 L of sample digest was injected onto a 50 ϫ 2.1 mm TARGA C18 column (Higgins Analytical). Chromatography was performed at a flow rate of 250 L/min. Total run time was 30 min. Mobile phases consisted of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in methanol). The chromatographic run started at 5% B for 2 min, followed by a 22-min linear gradient to 95% B, held at 95% B for 2 min, returned to 5% B in 0.5 min, and held there for 3.5 min. The first 5 min of the LC run were sent to waste, and data were collected for the next 16 min, before again diverting the last 9 min of the LC run to waste. The API 5000 instrument source parameters were CAD: 12, CUR: 40, GS1: 20, GS2: 25, IS: 5500, TEM: 600 and EP: 10. The doublycharged precursor ion for Corresponding transitions were monitored for the 15 NrHSA internal standard with the appropriate mass shifts: LVNEVTEFAK, Q1 mass shift of ϩ12 and respective mass-shifted Q3 ions; a 2 -ion ϩ2 (187.16), b 2 -ion ϩ2 (215.16), y 5 -ion ϩ6 (601.31), and y 8 -ion ϩ10 (947.46); QTALVELVK, Q1 mass shift of ϩ10 and respective mass-shifted Q3 ions; y 1 -ion ϩ2 (149.11), y 5 -ion ϩ6 (593.38), and y 6 -ion ϩ7 (707.46). We monitored tryptic peptides from the internal standard 15 NrHSA using the same conditions listed above for the native peptides.
STUDY POPULATION
Unused human urine samples from those submitted to the Mayo Clinic Renal Function Laboratory by patients with clinical indications were acquired and separated into 3 groups based on the albumin concentration measured by the immunoturbidometric assay: normoalbuminuric (0 -25 mg/L, n ϭ 50), microalbuminuric (25-200 mg/L, n ϭ 50), and macroalbuminuric (Ͼ2000 mg/L, n ϭ 38) ranges. All samples were frozen at Ϫ80°C until assayed within 6 months by laboratorians blinded to the initial result. The Mayo Clinic Institutional Review Board approved the use of the above specimens.
LIMIT OF QUANTIFICATION AND LIMIT OF DETECTION
The LOQ for urine albumin was calculated as the response for digested HSA spiked into a charcoalstripped urine matrix and resulting in a CV Ͻ20%. The limit of detection was determined using 3 SDs from the background signal of a zero calibrator digest without the addition of 15 NrHSA.
STATISTICAL ANALYSIS
Regression analysis for method comparisons was performed using linear regression analysis along with Passing-Bablok regression analysis, which was generated with the statistical program Analyze-it ® version 2.12 (Analyze-it Software). 15 NrHSA peptides from a 50 mg/L calibrator are provided in Fig. 1 . The retention time for the LVNEVTEFAK peptide (plots A and B) was 8.5 min, whereas the QTALVELVK peptide (plots C and D) had an elution time of 9 min.
Results
We determined the concentration of albumin in patient urine samples by comparing the ratio of the urinary albumin to the peak area to the 15 NrHSA internal standard peak area and referencing to an external calibration curve. Calibration curves were determined using linear regression analysis with a 1/x weighting factor on Analyst ® software (Applied Biosystems). Representative calibration curves are shown for the LVNEVTEFAK y 5 -ion and the QTALVELVK y 5 -ion in Supplemental Fig. 1 of the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol55/issue6. Intraassay imprecision, determined by using 5 replicates of low, medium, and high controls, yielded CVs Ͻ12.4% for both peptides and their corresponding ions (online Supplemental Table 1 ). Interassay imprecision, determined by surveying calibrators and controls for a 10-day period, yielded CVs Ͻ15.2% for all ion pairs of the LVNEVTEFAK and QTALVELVK peptides (online Supplemental Table 2 ). The LOQ was determined using the calibration imprecision data over the course of 10 days. For all transitions, repeated measurements at 3.13 mg/L (45.1 nmol/L) resulted in CVs Ͻ14.1%; at lower concentrations the signal was found to deviate from linearity, and the CVs rose to more than 20%. Accounting for the final sample volume and 20-L injection, a column load of 176.9 fmol is the absolute LOQ. The limit of detection, determined as 3 SDs of the signal from a zero calibrator digest without the addition of 15 NrHSA, was 0.035 mg/L or 2.0 fmol using the same volume and column-loading convention as above. We performed recovery/linearity experiments by spiking a normoalbuminuric sample with stock HSA, and then diluting serially with the sample itself. Each sample and dilution was digested independently. Recovery data, in the clinically relevant range, are summarized in online Supplemental Table 3 along with the linear regression equations and correlation coefficients for each ion pair. LC-MS/MS results for 138 patient specimens were compared to immunoturbidometric results obtained on a Hitachi 912 chemistry analyzer. A Passing-Bablok comparison plot is shown in Fig. 2 for samples analyzed using the LVNETEFAK peptide ion transition 575.5-595.6. All other transitions along with the data generated from the QTALVELVK peptide transitions were comparable with this representative transition. Comparison data were then divided into the clinically relevant normoalbuminuric and microalbuminuric ranges. In the normoalbuminuric range there appears to be a positive bias (Fig. 3A) , which is also observed in the Bland-Altman plot (Fig. 3B) . Possible causes of this discrepancy include the curve-fitting parameters set in the chemistry analyzer program and poorer detection limit of the immunoturbidometric assay because it deviates from linear response below 25 mg/L (data not shown). In comparison, the LC-MS/MS method was linear to 3.13 mg/L (online Supplemental Fig. 1 ). Correlations for the microalbuminuric range are shown in Fig. 4 . A break in the comparison correlation occurs around 200 mg/L (Fig. 4A) , a region in which the immunoturbidometric method displays a higher bias. However, the chemistry analyzer performs a 1:10 dilution at 180 mg/L in order to remain within the assay dynamic range. Therefore, in this region of the curve the chemistry analyzer assay system appears to overestimate, which may account for the break in the correlation. The Bland-Altman analysis for the microalbuminuric range in Fig. 4B also suggests that results of the immunoturbidometric assays are increased across this range, as evidenced by the Ϫ11% mean bias. Only a few points travel into the positive bias region Ͼ0%. This result should not be attributable to the calibration differences, because the same calibrators were used in each system.
Comparison plots of patient results from the 2 different peptides were also generated and divided into the 3 states of albuminuria. The normoalbuminuric range (0 -25 mg/L) comparison (Figs. 5A and 5B) shows a positive bias in both the linear regression (Fig.  5A ) and the Bland-Altman (Fig. 5B) plots. The Bland- Altman displays a migrating bias from negative to positive as the concentrations increase and yields an average positive bias with the LVNEVTEFAK peptide. This systemic bias could theoretically be explained by method error because both peptides produced CVs of around 10% in this region of the curve. In the microalbuminuric range (25-200 mg/L) sample comparison results are randomly distributed about the mean (2.71%) (Figs. 5C and 5D ). However, differences Ͼ30% were observed for certain samples despite the fact that the LC-MS/MS assay had CVs of approximately 5% in this region. Therefore system error alone may not be the only factor contributing to the differences observed. For specimens in the macroalbuminuric range (Ͼ200 mg/L) the assay displayed a reasonable correlation (Fig. 6A) , and percentage differences were randomly distributed about the mean (Fig. 6B) . However, as with the normoalbuminuric samples, a slight positive bias was observed for the LVNEVTEFAK vs the QTALVELVK peptide.
Discussion
Our method for absolute quantification of albumin in urine by using protein cleavage LC-MS/MS appears to be a viable option for a clinical laboratory setting. This method provides a lower LOQ compared to an immunoturbidometric system using DiaSorin microalbumin reagents. This method also provides a high degree of analytical specificity because the LC-MS/MS methodology incorporates separation and specific mass transitions for the detection of each peptide, and the LVNEVTEFAK and QTALVELVK peptides are specific to HSA (accession # P02768, gi:113576). To the best of our knowledge this is the only report of data obtained using protein cleavage methodologies and an intact stable isotope-labeled recombinant internal standard for quantification of urinary albumin from several peptides. The previous method reported by our group using insource fragmentation LC-MS with BSA and 15 NrHSA internal standards for quantification afforded measurement of urinary albumin without any sample preparation (4, 15 ) . However, the previous method had a limit of quantification of 20 mg/L, and thus the assay performance fell short of analytical requirements needed for a clinical assay (5 ) . To enhance the quantification of albumin in the normoalbuminuric range (Ͻ25 mg/L), we developed a urinary albumin assay using protein cleavage LC-MS/MS. Results presented here demonstrate that this assay has an LOQ of 3.13 mg/L, well below the clinically relevant range, and also has a large dynamic range (3.13-200 mg/L).
Because our method incorporates a digestion step, it is theoretically possible that preexisting N-terminal and/or C-terminal albumin fragments present in urine could be measured, thereby falsely increasing results (17) (18) (19) . Truncated versions of albumin have also been detected in the serum of patients with pancreatitis (20 ) . To detect such forms in urine, the ratio of N-terminal and C-terminal albumin peptides could be compared, with any deviation from unity suggesting the presence of such preformed N-or C-terminal peptides. However, if the truncations were minimal it is still possible that these forms could contain both of the peptides that are monitored in this assay. In addition, posttranslational modifications within these assayed peptides would change their masses and therefore cause them to go undetected, thereby falsely lowering the experimental results. Any modifications to albumin that would inhibit digestion by trypsin for 2 peptides chosen could also present falsely low results. Any of the above possibilities could be contributing to the differences observed when results from the 2 peptides were compared (Figs. 5 and 6 ). Because the discrepancies between the albumin peptides we monitored were relatively minor, our data suggest the majority of albumin in urine is intact. However, other strategies and additional studies would have to be developed to definitively test these possibilities and detect the presence of these molecules in native urine to document their potential diagnostic and prognostic importance. With the above caveats in mind, the current LC-MS/MS method can serve as a clinical assay for intact albumin in urine, or more likely as a reference method.
Urinary albumin quantification is important because increased albumin excretion predicts an increased likelihood of progression to overt renal disease, and even an increased risk for nonrenal outcomes (e.g., cardiovascular events). Therefore, efforts to standardize this assay are a current priority, following the example for standardization of serum creatinine (21 ) . Our results demonstrate that LC-MS/MS after trypsin di- gestion is a viable option for a reference method to quantify urinary albumin.
